About InVitro International
InVitro International is a publicly listed company based in Irvine (United States) founded in 1996. Non-animal in-vitro tests for ocular and dermal irritants are developed. The company has 6 employees. Its Indian entity Invitro International Private Limited reported revenue of ₹3.97 Cr. InVitro International offers products and services including IRRITECTION Assay System, Corrositex, and Lab Services. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Proteomics. Similar companies include Nautilus Biotechnology, Somalogic and ProteinSimple; 3 of its 3 listed similar companies have raised funding.
Company details
InVitro International (IVRO) is a company focused on developing and marketing non-animal toxicity testing quantitative in-vitro tests for detection of ocular andor dermal irritants and corrosives. The company offers two detection tests and customized technology services (CTS). Its products : Irritection Assay System is a quantity test to detect, rank, and predict the ocular andor dermal irritants from either cosmetics, pharmaceuticals or any other consumer products while Corrositex test involves a biomembrane and chemical detection system that helps in determining the chemical corrosivity by becoming colored after chemical exposure. The company also provide consultancy services to their customers for the easy and smooth installation of the detection systems.
- Headquarters Irvine, United States
- Employees 6
- Stage Public
- SectorsHealthcare
- Website invitrointl.com
- Social LinkedIn X Facebook
- Legal Name Invitro International
- Indian entity revenue₹3.97 Cr
FY 2025 · +28% YoY
- Indian entity net profit₹29.6 Lakh
FY 2025 · 7% margin
- Indian entity EBITDA₹79 Lakh
FY 2025 · 20% margin
- Employee Count6
Associated legal entities of InVitro International
InVitro International operates through Invitro International Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Invitro International Private Limited CIN U01122KA1995PTC018270 | Active | 11 Jul 1995 | Bangalore, Karnataka | ₹4.0 Cr | 26 | 2 | View details |
Products & Services of InVitro International
InVitro International offers a comprehensive portfolio of products and services, including IRRITECTION Assay System, Corrositex, and Lab Services.
Quantitative method for predicting ocular and dermal irritancy of chemicals
Non-animal test for classifying skin corrosives under GHS standards
Customized services using in vitro data for toxicity assessments
Board of directors of Invitro International Private Limited (InVitro International)
Invitro International Private Limited is the primary company behind InVitro International. The board of Invitro International Private Limited currently have 2 directors; the longest-serving is Jitendra Prakash, appointed in 1995. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Jitendra Prakash DIN 01760271 | Whole-time director | 11 Jul 1995 | 31 yrs 4 mo | Invitro International Private Limited |
| Seema Prakash DIN 01664183 | Managing Director | 11 Jul 1995 | 31 yrs 4 mo | Invitro International Private Limited |
IPO & Listings of InVitro International
InVitro International is a publicly listed company on the OTC with ticker symbol IVRO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Dec 2003
- Listed onOTCMKTS: IVRO
- Listed entityInVitro International
- Exchange sectorHealth technology
- ISINUS4618531036
- Share price$0.06 (-7.69% on the day) · 2026-10-02
- Market capitalisation$1.3M
- Price to earnings21.4
- EPS (diluted, trailing year)$0.00
- Volume (last session)1,000
Financials of InVitro International
Figures of Invitro International Private Limited, the primary company behind InVitro International, for FY 2025. Revenue was ₹3.97 Cr (+28% year on year). Net profit was ₹29.6 Lakh (7% margin). EBITDA was ₹79 Lakh (20% margin). Revenue has grown at a compounded annual rate of -28% over three years and -2% over five years.
- ₹3.97 CrRevenue · FY 2025 · +28% YoY
- ₹29.6 LakhNet profit · 7% margin
- ₹79 LakhEBITDA · 20% margin
- ₹14 LakhPaid-up capital
- 26Employees (provident fund records)
- -28%Revenue CAGR, 3 years
- -2%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $878,940 | $121,980 | $92,830 |
| 2024 | $811,290 | $106,700 | $73,640 |
| 2023 | $792,630 | $1,550 | -$21,010 |
| 2022 | $853,510 | $21,280 | -$112,880 |
| 2021 | $1.0M | $95,990 | -$24,080 |
Balance sheet, profit and loss, cash flow and ratios of Invitro International Private Limited are on its company page.
Detailed financial statements for InVitro International
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to InVitro International
InVitro International has 3 listed similar companies in our database, 3 of them funded. They include Nautilus Biotechnology, Somalogic and ProteinSimple.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nautilus.bio | 2016 | Seattle, United States | $103.26M | 134 | A proteomics platform is developed for analyzing the human proteome. | |
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| proteinsimple.com | 2004 | San Jose, United States | $114.29M | 157 | Provider tools to help researchers with protein analysis |
Detailed similar companies of InVitro International
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of InVitro International
The website of InVitro International (invitrointl.com) receives about 3.3K visits a month.
- Monthly visits3.3K
▲ 128.7% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as InVitro International (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Invitro International
Complete news archive for InVitro International
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InVitro International
InVitro International was founded in 1996.
InVitro International is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
InVitro International has 6 employees.
The primary company behind InVitro International, Invitro International Private Limited, reported revenue of ₹3.97 Cr for FY 2025, up 28% year on year.
InVitro International (IVRO) is a company focused on developing and marketing non-animal toxicity testing quantitative in-vitro tests for detection of ocular andor dermal irritants and corrosives. The company offers two detection tests and customized technology services (CTS). Its products : Irritection Assay System is a quantity test to detect, rank, and predict the ocular andor dermal irritants from either cosmetics, pharmaceuticals or any other consumer products while Corrositex test involves a biomembrane and chemical detection system that helps in determining the chemical corrosivity by becoming colored after chemical exposure. The company also provide consultancy services to their customers for the easy and smooth installation of the detection systems.
InVitro International's top competitors include Somalogic, Nautilus Biotechnology and ProteinSimple.
InVitro International offers IRRITECTION Assay System, Corrositex, and Lab Services.
Yes, InVitro International is publicly traded on OTC under the ticker symbol IVRO.
InVitro International operates through Invitro International Private Limited.
The legal entities of InVitro International currently have 2 directors, including Jitendra Prakash, Seema Prakash.